VIRX
Viracta Therapeutics, Inc.0.0098
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
388.70KP/E (TTM)
-Basic EPS (TTM)
-1.10Dividend Yield
0%Recent Filings
8-K
Viracta winds down operations
Viracta Therapeutics terminated all employees effective February 5, 2025, to wind down operations, expecting $0.1 million in one-time charges for severance and benefits in Q1 2025. The entire board and key officers resigned, with turnaround specialist Craig R. Jalbert appointed as sole director and all major executives at $50,000 annual pay for three years. While exploring strategic alternatives for its programs, the wind down faces risks from uncertain timing and outcomes.
8-K
Nasdaq delists Viracta stock
Viracta Therapeutics received a Nasdaq delisting notice on January 31, 2025, due to prior failures in meeting the $1 minimum share price and $2.5 million stockholders' equity requirements, with trading suspension set for February 4, 2025. The stock will shift to the OTC Pink Open Market under VIRX, a far less liquid venue that could further erode its trading price and volume. Delisting caps a string of compliance woes. Nasdaq plans to file Form 25 post-appeal.
8-K
Viracta secures loan forbearance
Viracta Therapeutics entered a forbearance agreement on January 23, 2025, with lenders Oxford Finance and Silicon Valley Bank, applying $7.7 million plus $3.7 million in cash to its loan obligations, reducing principal to $3.5 million. Lenders forgo default remedies until February 5, 2025, while Viracta grants a security interest in intellectual property and adheres to a strict spending budget. This buys time amid prior defaults. Lenders hold leverage post-deadline.
8-K
Nasdaq audit compliance notice
Viracta Therapeutics received a Nasdaq notice on January 13, 2025, flagging noncompliance with audit committee rules after director Barry J. Simon's resignation on December 18, 2024. The company has until the earlier of its next annual meeting or December 18, 2025, to appoint a new independent director and regain compliance. Nasdaq's cure period offers breathing room. This governance hiccup could pressure investor confidence amid biotech volatility.
8-K
Loan default, trial closure
Viracta Therapeutics faces a $15.7 million loan acceleration after defaults under its 2021 agreement with Silicon Valley Bank and Oxford Finance, triggered on December 20, 2024. The company is closing its Phase 2 NAVAL-1 trial for Nana-val in EBV+ lymphomas to extend cash runway while exploring strategic alternatives like mergers or sales. Board member Barry J. Simon resigned December 18, 2024, without disagreements. No transaction outcome assured.
NBTX
Nanobiotix S.A.
22.32+0.18
NNVC
NanoViricides, Inc.
1.29+0.06
NUVB
Nuvation Bio Inc.
8.66+0.15
NVCT
Nuvectis Pharma, Inc.
7.69+0.04
TOVX
Theriva Biologics, Inc.
0.21+0.01
VERA
Vera Therapeutics, Inc.
48.30-0.91
VINC
Vincerx Pharma, Inc.
0.01+0.00
VIR
Vir Biotechnology, Inc.
6.48-0.24
VRAX
Virax Biolabs Group Limited
0.40-0.01
VXRT
Vaxart, Inc.
0.37+0.01